Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 3/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14398636 | 0.83 | KMT2A (0.35) | SLC2A1ADH1ASHBGADH1C | |
| SCHEMBL7201658 | 0.80 | ADH1A (0.39) | ADH1AADH1CEPHX1 | |
| SCHEMBL4382413 | 0.78 | ADH1A (0.36) | ADH1AADH1C | |
| SCHEMBL19333316 | 0.73 | ADH1A (0.40) | SLC2A1ADH1ASHBGADH1C | |
| SCHEMBL24378399 | 0.71 | ADH1A (0.34) | ADH1AADH1CEPHX1 | |
| SCHEMBL20988082 | 0.70 | SHBG (0.42) | SLC2A1ADH1ASHBGADH1C | |
| SCHEMBL10460375 | 0.69 | ADH1A (0.41) | ADH1AADH1C | |
| SCHEMBL14355686 | 0.69 | ADH1A (0.37) | ADH1AADH1CEPHX1 | |
| SCHEMBL3186493 | 0.69 | HRH3 (0.42) | ADH1AADH1C | |
| SCHEMBL13397455 | 0.69 | DRD2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | SLC2A1 4751/4885ADH1A 4633/4885SHBG 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.